Search global stocks & ETFs...Ctrl K
Learn Mode
ILMN
Stock Profile
07-29
Recommended Metric
Score Card
Explore Scores Tab
3.35
Average
Valuation Score
Key Score
2.00
Bad
Management
4.00
Good
Growth
4.00
Good
Profitability
5.00
Very Good
Fin. Health
1.00
Very Bad
Dividends
--
--
Analyst
2.00
Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$188.68
Baseline
High
$183.75
▼
-2.61%
Avg
$144.02
▼
-23.67%
Low
$95.95
▼
-49.15%
Analyst Ratings based on 28 Analysts
Strong Buy
829%
Buy
932%
Hold
829%
Sell
207%
Strong Sell
104%
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,600 full-time employees. The company went IPO on 2000-06-28. The firm's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. The company also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.Read More